SCHEMBL14545342

SCHEMBL14545342

Oc1cnc(-c2ccc(Cl)cc2)c(-c2ccc(Cl)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 7/20 0.49
KDM4E B2RXH2 2/20 0.46
GAA P10253 2/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ADORA2A P29274 1/20 0.42
CDH1 P12830 1/20 0.40
APC P25054 1/20 0.40
CTNNB1 P35222 1/20 0.40
TCF7L2 Q9NQB0 1/20 0.40
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 2/20 0.39
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GLA P06280 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10810770 0.80 CNR1 (0.54) CNR1KMT2AMEN1MAPTALDH1A1
SCHEMBL22532587 0.80 CNR1 (0.44) CNR1GAAADORA2AKMT2AMEN1
SCHEMBL2036410 0.79 CKS1B (0.53) CNR1LMNAL3MBTL1ADORA2AKMT2A
SCHEMBL30478423 0.79 CKS1B (0.53) CNR1LMNAL3MBTL1ADORA2AKMT2A
SCHEMBL4693817 0.79 KDM4E (0.48) CNR1KDM4EGAALMNAL3MBTL1
SCHEMBL10511681 0.76 ADORA2A (0.46) CNR1KDM4EGAALMNAL3MBTL1
SCHEMBL14545305 0.76 ADORA2A (0.56) CNR1KDM4EGAALMNAL3MBTL1
SCHEMBL5943078 0.76 CNR1 (0.46) CNR1KDM4EGAALMNAL3MBTL1
SCHEMBL5773432 0.74 CNR1 (0.62) CNR1CDH1APCCTNNB1TCF7L2
SCHEMBL4252470 0.74 CNR1 (0.58) CNR1KDM4EGAALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070078135-A1 Substituted heteroaryl CB1 antagonists NEUROGEN CORPORATION (US) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078135-A1 Substituted heteroaryl CB1 antagonists CNR1, CNR2, OPRL1 CNR1 1/4885KDM4E 1408/4885GAA 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.